Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Phathom Pharmaceuticals Inc (PHAT)

Phathom Pharmaceuticals Inc (PHAT)
4.05 x 2 4.57 x 10
Post-market by (Cboe BZX)
4.03 -0.20 (-4.73%) 04/17/25 [NASDAQ]
4.05 x 2 4.57 x 10
Post-market 4.03 unch (unch) 16:20 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
4.02
Day High
4.30
Open 4.30
Previous Close 4.23 4.23
Volume 956,100 956,100
Avg Vol 1,245,370 1,245,370
Stochastic %K 17.45% 17.45%
Weighted Alpha -56.06 -56.06
5-Day Change -0.08 (-1.95%) -0.08 (-1.95%)
52-Week Range 3.81 - 19.71 3.81 - 19.71
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 280,637
  • Shares Outstanding, K 69,637
  • Annual Sales, $ 55,250 K
  • Annual Income, $ -334,330 K
  • EBIT $ -277 M
  • EBITDA $ -274 M
  • 60-Month Beta 0.35
  • Price/Sales 5.32
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 174.92% ( +17.99%)
  • Historical Volatility 145.75%
  • IV Percentile 93%
  • IV Rank 46.99%
  • IV High 328.78% on 03/13/25
  • IV Low 38.56% on 10/07/24
  • Put/Call Vol Ratio 2.00
  • Today's Volume 90
  • Volume Avg (30-Day) 453
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 11,206
  • Open Int (30-Day) 10,188

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.15
  • Number of Estimates 2
  • High Estimate -1.13
  • Low Estimate -1.18
  • Prior Year -1.42
  • Growth Rate Est. (year over year) +19.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.81 +5.77%
on 04/10/25
Period Open: 4.84
6.89 -41.51%
on 03/28/25
-0.81 (-16.74%)
since 03/17/25
3-Month
3.81 +5.77%
on 04/10/25
Period Open: 6.96
7.25 -44.41%
on 01/24/25
-2.93 (-42.10%)
since 01/17/25
52-Week
3.81 +5.77%
on 04/10/25
Period Open: 9.80
19.71 -79.55%
on 09/19/24
-5.77 (-58.88%)
since 04/17/24

Most Recent Stories

More News
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

CDTX : 19.44 (+1.36%)
PHAT : 4.03 (-4.62%)
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

PHAT : 4.03 (-4.62%)
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHAT : 4.03 (-4.62%)
Phathom Pharmaceuticals Announces Leadership Succession

PHAT : 4.03 (-4.62%)
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

PHAT : 4.03 (-4.62%)
2 Growth Stocks to Buy Now With 367% to 410% Upside

Strong, innovative pipelines make these two biotech firms smart buys now.

$SPX : 5,282.70 (unch)
ARCT : 10.53 (+2.23%)
PHAT : 4.03 (-4.62%)
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

PHAT : 4.03 (-4.62%)
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

PHAT : 4.03 (-4.62%)
2 ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%

These biotech companies are poised for significant long-term growth. However, there are risks.

$SPX : 5,282.70 (unch)
STOK : 7.69 (+1.72%)
ACAD : 14.73 (+1.10%)
PHAT : 4.03 (-4.62%)
BIIB : 118.61 (+2.88%)
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

PHAT : 4.03 (-4.62%)

Business Summary

Phathom Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel treatments for gastrointestinal diseases. The company's product pipeline consists of vonoprazan, which are in clinical stage. Phathom Pharmaceuticals Inc. is based in Buffalo...

See More

Key Turning Points

3rd Resistance Point 4.49
2nd Resistance Point 4.40
1st Resistance Point 4.21
Last Price 4.03
1st Support Level 3.93
2nd Support Level 3.84
3rd Support Level 3.65

See More

52-Week High 19.71
Fibonacci 61.8% 13.64
Fibonacci 50% 11.76
Fibonacci 38.2% 9.88
Last Price 4.03
52-Week Low 3.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro